A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/22/2018 |
| Start Date: | April 2015 |
| End Date: | August 2016 |
Early Onset of Clinical Improvement With Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque
psoriasis and to document the same using sequential photographic images.
psoriasis and to document the same using sequential photographic images.
Inclusion Criteria:
- Present with chronic moderate-to-severe plaque psoriasis based on a confirmed (by a
dermatologist) diagnosis of chronic plaque psoriasis for at least 6 months prior to
baseline
- Active psoriatic skin lesions of plaque psoriasis (Ps)
- Are a candidate for phototherapy and/or systemic therapy
- Men must agree to use a reliable method of birth control or remain abstinent during
the study and for at least 12 weeks after stopping treatment
- Women must agree to use reliable birth control or remain abstinent during the study
and for at least 12 weeks after stopping treatment
Exclusion Criteria:
- Are unable to commit to the photography schedule for the duration of the study
- Have participated in any study with interleukin 17 (IL-17) or (IL-23) antagonists,
including ixekizumab
- Serious disorder or illness other than psoriasis
- Serious infection within the last 3 months
- Breastfeeding or nursing (lactating) women
We found this trial at
1
site
Click here to add this to my saved trials
